Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

There is an urgent need for novel targeted therapy for osteosarcoma (OS). Molecular targeted therapy has yielded stunning response rates of >90% for specific targets such as NTRK gene fusions. In contrast, the mainstay of therapy for osteosarcoma has remained the same for more than 30 years and few targeted agents have successfully translated to the clinic for OS patients.

The challenge to develop targeted therapies for osteosarcoma is that the tumor has different driver mutations in different patients. However, 12-39% of tumors share a common amplification in a gene called MYC. In this project, Dr. Grohar and colleagues will consider this subset of osteosarcoma as a distinct entity. They are characterizing the role of MYC in the pathogenesis of osteosarcoma and determining how MYC makes osteosarcoma aggressive. Ultimately, they will identify compounds that will serve as clinical candidates for MYC-driven osteosarcoma. They will then determine if they are best translated to the clinic as single agents, in combination with chemotherapy, or as metastasis-targeted therapy.

Dr. Grohar has assembled a team with the necessary expertise. Chand Khanna is a disease expert in osteosarcoma, the Grohar lab has expertise in drug development for bone sarcomas, the Neamati and O'Keefe labs are experts in drug discovery/chemical biology/natural products. Filemon Dela Cruz is an expert in preclinical drug modeling, Ted Laetsch and Rashmi Chugh are experts in sarcoma clinical trial design, and Ethos (led by Chand Khanna) and Vuja De (led by David Warshawsky) are companies that will aid in the development of these compounds for the clinic. Together they will identify compounds that are specific and effective for MYC amplified osteosarcoma. This grant was awarded at Children's Hospital of Philadelphia and transferred to the University of Michigan.

To make a significant impact for kids fighting osteosarcoma, five funding partners have banded together with St. Baldrick’s to support this grant – The Fight Osteosarcoma Together (FOT) Super Grant supported by Battle Osteosarcoma, CureSearch for Children’s Cancer, Michael and April Egge, The Osteosarcoma Collaborative, and the Zach Sobiech Osteosarcoma Fund of Children’s Cancer Research Fund.

Burkitt lymphoma (BL) is the fastest growing, most aggressive pediatric tumor. In the 1960s, it was universally fatal. Over the past decades, clinical trials identified very high dose chemotherapy therapies as effective. Over 95% of children with BL in the US now survive. However, over 80% of cases of BL arise in children in sub-Saharan Africa (SSA) and other lower income regions where high dose chemotherapy is not currently feasible and in these settings BL is typically fatal. In the study, Dr. Allen builds on the observation that BL tumors from US and SSA are largely indistinguishable, but surprisingly tonsils from children in SSA and US have vastly different gene expression patterns. He therefore hypothesizes that the much higher rate of BL in SSA may not be due to intrinsic cancer cell factors, rather due to the nature of lymphoid tissues out of which the cancer cells grow. If Dr. Allen and colleagues can identify factors that lead to BL, they hope to create opportunities to prevent and treat BL in SSA.

This grant is funded by Danilo Gallinari and the National Basketball Players Association.

This proposal introduces four groundbreaking advancements in the treatment of Ewing sarcoma (EwS), a rare and aggressive cancer. Firstly, Dr. Li and colleagues aim to optimize and assess the effectiveness of cutting-edge anti-IL1RAP ADCs in treating EwS. Secondly, they seek to uncover new insights into the diversity and heterogeneity of targets within EwS tumors. Thirdly, will explore the potential of innovative bispecific ADCs to target a wider range of EwS cells, enhancing treatment efficacy and reducing the risk of relapse and spread. Lastly, Dr. Li will explore the possibility of applying these advancements to other IL1RAP+CD276+ cancers like acute myeloid leukemia (AML). Overall, this research holds promise for improving outcomes and broadening treatment options for patients with these challenging cancers. This grant is funded by and named for the D-Feet Cancer - The Dalton Fox Foundation. D-Feet Cancer - The Dalton Fox Foundation was established to honor and remember Dalton’s contagious smile and sense of humor, even on his toughest days with Ewing Sarcoma. He is an inspiration and the reason for the mission and interest in finding targeted therapies and treatments for Ewing Sarcoma, a pediatric bone cancer.

Fortunately, the majority of children with cancer are cured with the standard or primary treatment of their cancer. This is largely due to improvement in outcomes over time through cooperative group studies through a national organization called Children's Oncology Group (COG). COG studies are very labor intensive and therefore require significant amounts of resources and research staff to ensure all children with cancer eligible for COG studies are able to be enrolled on these studies. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Clinical research associates are the cornerstone of clinical research who helps to open new clinical trials, maintain trials, and enroll patients. This grant supports a Clinical Research Associates at El Paso Children's hospital to facilitate clinical research in children with cancer.

This grant supports a data manager who will help ensure clinical trial data is complete, timely, and of the highest quality. This will allow the clinical research coordinators to focus on enrolling patients, ensuring more children have access to the most cutting edge treatments, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a pediatric-focused Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a survivorship program Clinical Research Associate to ensure that more kids are offered enrollment onto appropriate registry, late effects, and supportive care clinical trials.

This grant supports an Adolescent Young Adult (AYA) Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant will support resources for the Bone and Marrow Transplantation (BMT) team at Children's National to share the importance of clinical trials, as well as cover key information pertaining to the BMT journey. This will help more kids can be treated on clinical trials, often their best hope for a cure.

St. Joseph's Children's Hospital serves a diverse, economically-challenged population. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. The Clinical Research Associate will help increase patients' participation in pediatric oncology clinical trials and will help add to the knowledge base around minority patients who are often underrepresented in research.

The Loma Linda University Children's Hospital (LLUCH) services a four-county region (San Bernardino, Riverside, Inyo and Mono Counties). For the 1.3 million children living in this region, 25% come from families that live in poverty and are uninsured. This population represents 80% of the children treated here. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. The participation of this patient population in clinical trials is critical for the identification of therapies that can alleviate this health disparity and effectively treat all children.